Overview

Paediatric VLA2001-321 Study

Status:
Not yet recruiting
Trial end date:
2025-04-30
Target enrollment:
Participant gender:
Summary
This is a Randomized, Double-blinded, Active-controlled Study to evaluate the Safety, Tolerability and Immunogenicity of VLA2001 in participants of ≥2 to 12 years. In total 1720 participants will receive either VLA2001 or active Comparator.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Valneva Austria GmbH